Corresponding results supported that indirubin might exert therapeutic effects on ITP by regulating the homeostasis of the PD-1/PTEN/AKT signaling pathway in CD4+ T cells. This evidence concerns the gene AKT1 and autoimmune thrombocytopenic purpura.